Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ERY066
MIFTS: 29

Erythema Multiforme Major

Categories: Rare diseases, Skin diseases
Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Erythema Multiforme Major

About this section

MalaCards integrated aliases for Erythema Multiforme Major:

Name: Erythema Multiforme Major 59 72
Erythema Exsudativum Multiforme Majus 59
Erythema Multiforme Majus 59
Stevens-Johnson Syndrome 72

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
Orphanet: 59  
Rare skin diseases


External Ids:

Orphanet 59 ORPHA502499
UMLS 72 C0038325 C3241919
Sources

Summaries for Erythema Multiforme Major

About this section
MalaCards based summary : Erythema Multiforme Major, also known as erythema exsudativum multiforme majus, is related to erythema multiforme and severe cutaneous adverse reaction. The drugs Gabapentin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Sources

Related Diseases for Erythema Multiforme Major

About this section

Diseases related to Erythema Multiforme Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 erythema multiforme 11.8
2 severe cutaneous adverse reaction 10.5
3 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.5
4 exanthem 10.4
5 herpes simplex 10.3
6 stevens-johnson syndrome/toxic epidermal necrolysis 10.3
7 vascular disease 10.2
8 neutropenia 10.1
9 skin disease 10.1
10 bullous pemphigoid 10.1
11 pemphigus 10.1
12 autoimmune disease 10.0
13 major affective disorder 1 10.0
14 renal cell carcinoma, nonpapillary 10.0
15 immune deficiency disease 10.0
16 yemenite deaf-blind hypopigmentation syndrome 10.0
17 meningioma, radiation-induced 10.0
18 meningioma, familial 10.0
19 nail disorder, nonsyndromic congenital, 10 10.0
20 chlamydia pneumonia 10.0
21 pemphigus gestationis 10.0
22 disseminated intravascular coagulation 10.0
23 chlamydia 10.0
24 spinal meningioma 10.0
25 cicatricial pemphigoid 10.0
26 allergic hypersensitivity disease 10.0
27 locked-in syndrome 10.0
28 quadriplegia 10.0
29 pemphigoid gestationis 10.0
30 thrombocytopenia 10.0
31 melanoma 10.0
32 focal epilepsy 10.0
33 systemic scleroderma 10.0
34 secretory meningioma 10.0
35 lymphoplasmacyte-rich meningioma 10.0
36 pneumonia 10.0
37 conjunctivitis 10.0
38 acquired immunodeficiency syndrome 10.0
39 epilepsy with generalized tonic-clonic seizures 10.0
40 impetigo 10.0
41 herpes zoster 10.0
42 crohn's disease 10.0
43 alopecia areata 10.0
44 alopecia 10.0
45 neisseria meningitidis infection 10.0
46 bullous impetigo 10.0
47 acute liver failure 10.0

Graphical network of the top 20 diseases related to Erythema Multiforme Major:



Diseases related to Erythema Multiforme Major
Sources

Symptoms & Phenotypes for Erythema Multiforme Major

About this section
Sources

Drugs & Therapeutics for Erythema Multiforme Major

About this section

Drugs for Erythema Multiforme Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
5
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
8 Ophthalmic Solutions Phase 4
9 Antimetabolites Phase 4
10 Anti-Bacterial Agents Phase 4
11 Analgesics Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Psychotropic Drugs Phase 4
14 Tranquilizing Agents Phase 4
15 Central Nervous System Depressants Phase 4
16 Anti-Anxiety Agents Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Anticonvulsants Phase 4
19 Antimanic Agents Phase 4
20 Excitatory Amino Acids Phase 4
21 Analgesics, Opioid Phase 4
22 Cytochrome P-450 Enzyme Inducers Phase 4
23 Lipid Regulating Agents Phase 4
24 Hypolipidemic Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Neurotransmitter Agents Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Sodium Channel Blockers Phase 4
29 Autonomic Agents Phase 4
30 Anti-Arrhythmia Agents Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Adrenergic Agents Phase 4
33 Adrenergic Antagonists Phase 4
34 Sympatholytics Phase 4
35
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
36
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
37
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
38
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
39
Etravirine Approved Phase 3 269055-15-4 193962
40
tannic acid Approved Phase 2, Phase 3 1401-55-4
41
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
42
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
43
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
44
Etanercept Approved, Investigational Phase 3 185243-69-0
45
Coal tar Approved Phase 3 8007-45-2
46
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
47
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
48 Hypoglycemic Agents Phase 3
49 Antirheumatic Agents Phase 3
50 Renal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
8 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
16 Phase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in Adults Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
17 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
19 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
20 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
21 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
22 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
23 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
24 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
25 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
26 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
27 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
28 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
29 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
30 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
31 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
32 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
33 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
34 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
35 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
36 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
37 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
38 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
39 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
40 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
41 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Isotretinoin
42 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
43 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
44 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597
45 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
46 Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting Recruiting NCT03041883
47 Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A) Recruiting NCT03445312
48 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
49 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison
50 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Not yet recruiting NCT03304366

Search NIH Clinical Center for Erythema Multiforme Major

Sources

Genetic Tests for Erythema Multiforme Major

About this section
Sources

Anatomical Context for Erythema Multiforme Major

About this section

MalaCards organs/tissues related to Erythema Multiforme Major:

41
Skin, Eye, Testes, T Cells, Liver, Lung, Salivary Gland
Sources

Publications for Erythema Multiforme Major

About this section

Articles related to Erythema Multiforme Major:

(show top 50) (show all 3381)
# Title Authors PMID Year
1
Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. 38
30632424 2019
2
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. 38
30086678 2019
3
Predicting sepsis in Stevens-Johnson syndrome-toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin? 38
31420075 2019
4
Histomorphological Changes in Lachrymal Glands of Patients With Chronic Stevens-Johnson Syndrome. 38
31232745 2019
5
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. 38
30809807 2019
6
Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. 38
30825193 2019
7
Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma. 38
31198688 2019
8
Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. 38
31150704 2019
9
Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. 38
31195022 2019
10
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 38
31254013 2019
11
Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. 38
31332981 2019
12
Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study. 38
30998617 2019
13
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 38
29912772 2019
14
Contribution to oral and maxillary surgery and surgical technique of osteo-odontokeratoprosthesis in Japan. 38
31378404 2019
15
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 38
30785787 2019
16
Stevens-Johnson Syndrome and Treatment With Clopidogrel. 38
30119955 2019
17
Altered retinoid metabolism gene expression in chronic Stevens-Johnson syndrome. 38
31023710 2019
18
Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure. 38
31404173 2019
19
Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. 38
31436331 2019
20
Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. 38
31041733 2019
21
Nursing problems in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome in a Dutch burn centre: A 30-year retrospective study. 38
31387802 2019
22
Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate. 38
31396952 2019
23
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 38
30918988 2019
24
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. 38
31434673 2019
25
Drug hypersensitivity in HIV infection. 38
31145192 2019
26
HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol-A Canadian Missed Opportunity. 38
31378082 2019
27
Long-term effect of corneoscleral contact lenses on refractory ocular surface diseases. 38
30389416 2019
28
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 38
31387950 2019
29
A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. 38
31241804 2019
30
Identification of drug-specific public TCR driving severe cutaneous adverse reactions. 38
31395875 2019
31
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. 38
31020549 2019
32
Making a diagnosis in severe cutaneous drug hypersensitivity reactions. 38
31247634 2019
33
[Warning symptoms skin: cutaneous manifestation of drug allergy]. 38
31282839 2019
34
Corneal higher-order aberrations in Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
31325631 2019
35
[Allergies to non-betalactam antibiotics: a challenge in practice]. 38
31282834 2019
36
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. 38
31327687 2019
37
Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi-review of the literature illustrated by clinical cases. 38
31352606 2019
38
Long-term impact of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
31326519 2019
39
Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction. 38
31356413 2019
40
Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. 38
31384575 2019
41
Erythema Multiforme: Recognition and Management. 38
31305041 2019
42
Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series. 38
31070856 2019
43
Multistep Grading System for Evaluation of Chronic Ocular Sequelae in Patients With Stevens-Johnson Syndrome. 38
30731084 2019
44
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. 38
31342541 2019
45
Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab. 38
31334834 2019
46
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. 38
31308200 2019
47
How different is Stevens-Johnson syndrome/toxic epidermal necrolysis in children? 38
31259411 2019
48
A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy. 38
31290394 2019
49
Coxsackievirus B5-induced severe mucocutaneous reaction mimicking drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
31062724 2019
50
Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
30633324 2019
Sources

Variations for Erythema Multiforme Major

About this section
Sources

Expression for Erythema Multiforme Major

About this section
Search GEO for disease gene expression data for Erythema Multiforme Major.
Sources

Pathways for Erythema Multiforme Major

About this section
Sources

GO Terms for Erythema Multiforme Major

About this section
Sources

Sources for Erythema Multiforme Major

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....